Korean Journal of Radiology

  • 제25권9호
  • /
  • Pages.824-832
  • /
  • 2024
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

Changing Gadolinium-Based Contrast Agents to Prevent Recurrent Acute Adverse Drug Reactions: 6-Year Cohort Study Using Propensity Score Matching

  • Min Woo Han (University of Ulsan College of Medicine) ;
  • Chong Hyun Suh (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Pyeong Hwa Kim (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Seonok Kim (Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Ah Young Kim (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Kyung-Hyun Do (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Jeong Hyun Lee (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Dong-Il Gwon (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Ah Young Jung (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Choong Wook Lee (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center)
  • 투고 : 2023.12.29
  • 심사 : 2024.07.04
  • 발행 : 2024.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To determine the preventive effect of changing gadolinium-based contrast agents (GBCAs) to reduce the recurrence of GBCA-associated acute adverse drug reactions (ADRs). Materials and Methods: This retrospective, observational, single-center study-conducted between January 2016 and December 2021-included 238743 consecutive GBCA-enhanced MRI examinations. We focused on a subgroup of patients who experienced acute GBCA-associated ADRs during any of these examinations and subsequently underwent follow-up GBCA-enhanced MRI examinations up until July 2023. The follow-up examinations involved either the same (non-change group) or different (change group) GBCAs compared to the ones that initially caused the acute ADR. Baseline participant characteristics, generic profile of the GBCAs, administration of premedication, history of prior ADR to iodinated contrast media, and symptoms of GBCA-associated acute ADRs were retrospectively analyzed. Multivariable logistic regression with generalized estimating equations and propensity score matching were used. Results: A total of 1042 instances of acute ADRs (0.44%; 95% confidence interval [CI]: 0.41%-0.46%) were reported. Three-hundred and seventy-three patients underwent GBCA-enhanced MRI examinations after experiencing GBCA-associated acute ADRs within the study period; 31.9% (119/373) reexperienced acute ADRs at any of the follow-up examinations. The ADR recurrence was significantly lower in the GBCA change group than in the non-change group according to multivariable logistic regression (adjusted odds ratio [OR]: 0.35; 95% CI: 0.13-0.90; P = 0.03) and analysis with propensity score matching (14.3% [6/42] vs. 36.9% [31/84], respectively; OR: 0.32, 95% CI: 0.11-0.94; P = 0.04). A history of an ADR to iodinated contrast media (OR: 1.14, 95% CI: 0.68-1.90; P = 0.62) and premedication (adjusted OR: 2.09, 95% CI: 0.93-4.68; P = 0.07) were not significantly associated with GBCA-associated acute ADR recurrence. A separate analysis for recurrent allergic-like hypersensitivity reactions demonstrated similar results (adjusted OR: 0.20, 95% CI: 0.06-0.65; P < 0.01). Conclusion: Changing GBCAs may reduce the risk of GBCA-associated acute ADR recurrence.

키워드

참고문헌

  1. Behzadi AH, Zhao Y, Farooq Z, Prince MR. Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology 2018;286:471-482 
  2. Oh SW, Park SY, Yong HS, Choi YH, Cha MJ, Kim TB, et al. [Korean clinical practice guidelines for adverse reactions to intravenous iodinate and MRI-gadolinium contrast agents: revised clinical consensus and recommendations (3rd edition, 2022)]. J Korean Soc Radiol 2022;83:254-264. Korean 
  3. Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN. Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients. Radiology 2011;259:109-116 
  4. Kanny G, Pichler W, Morisset M, Franck P, Marie B, Kohler C, et al. T cell-mediated reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests. J Allergy Clin Immunol 2005;115:179-185 
  5. Ryoo CH, Choi YH, Cheon JE, Yoon SH, Kang HR, Park SJ, et al. Preventive effect of changing contrast media in patients with a prior mild immediate hypersensitivity reaction to gadolinium-based contrast agent. Invest Radiol 2019;54:633-637 
  6. Ahn YH, Kang DY, Park SB, Kim HH, Kim HJ, Park GY, et al. Allergic-like hypersensitivity reactions to gadolinium-based contrast agents: an 8-year cohort study of 154539 patients. Radiology 2022;303:329-336 
  7. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W163-W194 
  8. Kim PH, Suh CH, Jang EB, Kim S, Park KJ, Park HJ, et al. N-(2,3-dihydroxypropyl) carbamoyl side chain: a potentially significant factor for recurrent iodinated contrast medium-related adverse drug reactions. Eur Radiol 2024 Apr 16 [Epub]. https://doi.org/10.1007/s00330-024-10730-7 
  9. Baek S, Park SH, Won E, Park YR, Kim HJ. Propensity score matching: a conceptual review for radiology researchers. Korean J Radiol 2015;16:286-296 
  10. The Contrast Media Safety Committee. ESUR guidelines on contrast agents [accessed on December 1, 2023]. Available at: https://www.esur.org/esur-guidelines-on-contrast-agents 
  11. Park SJ, Kang DY, Sohn KH, Yoon SH, Lee W, Choi YH, et al. Immediate mild reactions to CT with iodinated contrast media: strategy of contrast media readministration without corticosteroids. Radiology 2018;288:710-716 
  12. Numan L, Loku Galappaththy S, Husainat NM, Abu Ghanimeh M. Idiopathic intestinal angioedema: a diagnostic dilemma. Cureus 2019;11:e4951 
  13. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977;1:466-469 
  14. Sodagari F, Mozaffary A, Wood CG 3rd, Schmitz B, Miller FH, Yaghmai V. Reactions to both nonionic iodinated and gadolinium-based contrast media: incidence and clinical characteristics. AJR Am J Roentgenol 2018;210:715-719 
  15. Nelson KL, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA. Clinical safety of gadopentetate dimeglumine. Radiology 1995;196:439-443 
  16. Kolenda C, Dubost R, Hacard F, Mullet C, Le Quang D, Garnier L, et al. Evaluation of basophil activation test in the management of immediate hypersensitivity reactions to gadolinium-based contrast agents: a five-year experience. J Allergy Clin Immunol Pract 2017;5:846-849 
  17. Walker DT, Davenport MS, McGrath TA, McInnes MDF, Shankar T, Schieda N. Breakthrough hypersensitivity reactions to gadolinium-based contrast agents and strategies to decrease subsequent reaction rates: a systematic review and meta-analysis. Radiology 2020;296:312-321 
  18. McDonald JS, Hunt CH, Kolbe AB, Schmitz JJ, Hartman RP, Maddox DE, et al. Acute adverse events following gadolinium-based contrast agent administration: a single-center retrospective study of 281 945 injections. Radiology 2019;292:620-627 
  19. Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol--a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur J Radiol 2010;74:e186-e192